Clinical outcomes of first-line antiretroviral therapy in Latin America : analysis from the LATINA retrospective cohort study
© The Author(s) 2015..
Nearly 2 million people are infected with human immunodeficiency virus (HIV) in Latin America. However, information regarding population-scale outcomes from a regional perspective is scarce. We aimed to describe the baseline characteristics and therapeutic outcomes of newly-treated individuals with HIV infection in Latin America. A Retrospective cohort study was undertaken. The primary explanatory variable was combination antiretroviral therapy based on either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The main outcome was defined as the composite of all-cause mortality and the occurrence of an AIDS-defining clinical event or a serious non-AIDS-defining event during the first year of therapy. The secondary outcomes included the time to a change in treatment strategy. All analyses were performed according to the intention to treat principle. A total of 937 treatment-naive patients from four participating countries were included (228 patients with PI therapy and 709 with NNRTI-based treatment). At the time of treatment initiation, the patients had a mean age of 37 (SD: 10) years and a median CD4 + T-cell count of 133 cells/mm(3) (interquartile range: 47.5-216.0). Patients receiving PI-based regimens had a significantly lower CD4 + count, a higher AIDS prevalence at baseline and a shorter time from HIV diagnosis until the initiation of treatment. There was no difference in the hazard ratio for the primary outcome between groups. The only covariates associated with the latter were CD4 + cell count at baseline, study site and age. The estimated hazard ratio for the time to a change in treatment (NNRTI vs PI) was 0.61 (95% CI 0.47-0.80, p < 0.01). This study concluded that patients living with HIV in Latin America present with similar clinical outcomes regardless of the choice of initial therapy. Patients treated with PIs are more likely to require a treatment change during the first year of follow up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
International journal of STD & AIDS - 27(2016), 2 vom: 05. Feb., Seite 118-26 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Angriman, Federico [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AIDS |
|---|
| Anmerkungen: |
Date Completed 05.05.2016 Date Revised 16.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/0956462415575621 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM246790156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246790156 | ||
| 003 | DE-627 | ||
| 005 | 20231224143826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0956462415575621 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0822.xml |
| 035 | |a (DE-627)NLM246790156 | ||
| 035 | |a (NLM)25740759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Angriman, Federico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of first-line antiretroviral therapy in Latin America |b analysis from the LATINA retrospective cohort study |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.05.2016 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2015. | ||
| 520 | |a Nearly 2 million people are infected with human immunodeficiency virus (HIV) in Latin America. However, information regarding population-scale outcomes from a regional perspective is scarce. We aimed to describe the baseline characteristics and therapeutic outcomes of newly-treated individuals with HIV infection in Latin America. A Retrospective cohort study was undertaken. The primary explanatory variable was combination antiretroviral therapy based on either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The main outcome was defined as the composite of all-cause mortality and the occurrence of an AIDS-defining clinical event or a serious non-AIDS-defining event during the first year of therapy. The secondary outcomes included the time to a change in treatment strategy. All analyses were performed according to the intention to treat principle. A total of 937 treatment-naive patients from four participating countries were included (228 patients with PI therapy and 709 with NNRTI-based treatment). At the time of treatment initiation, the patients had a mean age of 37 (SD: 10) years and a median CD4 + T-cell count of 133 cells/mm(3) (interquartile range: 47.5-216.0). Patients receiving PI-based regimens had a significantly lower CD4 + count, a higher AIDS prevalence at baseline and a shorter time from HIV diagnosis until the initiation of treatment. There was no difference in the hazard ratio for the primary outcome between groups. The only covariates associated with the latter were CD4 + cell count at baseline, study site and age. The estimated hazard ratio for the time to a change in treatment (NNRTI vs PI) was 0.61 (95% CI 0.47-0.80, p < 0.01). This study concluded that patients living with HIV in Latin America present with similar clinical outcomes regardless of the choice of initial therapy. Patients treated with PIs are more likely to require a treatment change during the first year of follow up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AIDS | |
| 650 | 4 | |a CD4 cell lymphocyte count | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Latin America | |
| 650 | 4 | |a antiretroviral therapy | |
| 650 | 4 | |a cohort studies | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 700 | 1 | |a Belloso, Waldo H |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra-Madero, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira, Ronaldo Ismerio |e verfasserin |4 aut | |
| 700 | 1 | |a Kovalevski, Leandro O |e verfasserin |4 aut | |
| 700 | 1 | |a Orellana, Liliana C |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Sandra Wagner |e verfasserin |4 aut | |
| 700 | 1 | |a Crabtree-Ramirez, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a La Rosa, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Losso, Marcelo H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of STD & AIDS |d 1991 |g 27(2016), 2 vom: 05. Feb., Seite 118-26 |w (DE-627)NLM012641960 |x 1758-1052 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g number:2 |g day:05 |g month:02 |g pages:118-26 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/0956462415575621 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2016 |e 2 |b 05 |c 02 |h 118-26 | ||